8-K current report · filed Nov 12, 2026

CorMedix Inc. (CRMD) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1CRMD overview

Short answer

CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). CorMedix announced financial results for the quarter ended September 30, 2026.

CorMedix Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • CorMedix announced financial results for the quarter ended September 30, 2026
  • Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
  • DefenCath revenue $17.2M, including a $5.0M favorable sales-allowance estimate change, signaling underlying pricing sensitivity
  • Net loss $14.7M and adjusted EBITDA $3.1M, sharply below prior-year adjusted EBITDA $71.9M
  • FY 2026 revenue guidance maintained at $325M-$345M, while adjusted EBITDA guidance narrowed to $130M-$140M
  • Heron asset acquisition expected in Q1 2027, with projected 2027 revenue contribution of $125M-$150M and up to $150M term-loan capacity

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CorMedix Inc. 8-K filings

Get the next CRMD 8-K as it lands

Follow CRMD for push alerts, or ask the research agent what this filing means.